BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
BioSpace
BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.
pharminent
April 3, 2026 (Last updated: April 3, 2026)
BioSpace
BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.